NASDAQ : RADX
Radiopharm Theranostics Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 1.1164 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 21.29M |
| Enterprise Value | 14.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 26, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.34B |
| Shares Change (YoY) | +47.68% |
| Shares Change (QoQ) | +39.34% |
| Owned by Insiders (%) | 4.85% |
| Owned by Institutions (%) | 8.46% |
| Float | 3.59B |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.44 |
| Forward PS | 3.42 |
| PB Ratio | 1.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.16 |
| Quick Ratio | 1.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -471.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -174.71% |
| Return on Assets (ROA) | -45.15% |
| Return on Invested Capital (ROIC) | -101.54% |
| Return on Capital Employed (ROCE) | -128.42% |
| Weighted Average Cost of Capital (WACC) | 8.98% |
| Revenue Per Employee | $635,723 |
| Profits Per Employee | -$2.81M |
| Employee Count | 14 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 37,662 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -78.71% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 3.66 |
| Relative Strength Index (RSI) | 43.62 |
| Average Volume (20 Days) | 40,700 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 141,864 |
| Short Previous Month | 34,322 |
| Short % of Shares Out | 1.01% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.21 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.90M |
| Gross Profit | -23.75M |
| Operating Income | -36.64M |
| Pretax Income | -39.36M |
| Net Income | -39.40M |
| EBITDA | -34.76M |
| EBIT | -36.64M |
| Loss Per Share | -$3.90 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.86M |
| Total Debt | n/a |
| Net Cash | 2.86M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 15.44M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -37.06M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.90M |
| Net Borrowing | n/a |
| Free Cash Flow | -37.06M |
| FCF Per Share | -$0.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | -266.89% |
| Operating Margin | -411.63% |
| Pretax Margin | -442.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.68% |
| Shareholder Yield | -47.68% |
| Earnings Yield | -368.20% |
| FCF Yield | -170.87% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.04 |
| Price Target Difference | 1,507.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 246.53% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.16 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |